ASS1 and glioblastoma: In vivo experiments to evaluate the effect of ADI-PEG20 combined with IR in ASS1-positive GBM yielded striking results, where we observed highly significant tumor responses compared with control animals and monotherapy groups, as evidenced by epifluorescence, BLI, measurement of GFP histopathology, and most importantly, survival.